Aurobindo Pharma Limited has submitted its quarterly compliance certificate to the National Stock Exchange of India Limited and BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The pharmaceutical company filed its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 9, 2026, covering the quarter ended March 31, 2026. The certificate was signed by B. Adi Reddy, Company Secretary, and submitted to both major stock exchanges where the company's shares are traded.

Certificate Confirmation

The filing certifies that details of securities dematerialized and rematerialized during the quarter ended March 31, 2026 have been properly furnished to all stock exchanges where the company's shares are listed. This compliance ensures transparency in the dematerialization and rematerialization process of the company's securities.

Supporting Documentation

The submission included supporting certificates from KFin Technologies Limited, the company's Registrar and Transfer Agent, dated April 1, 2026. KFin Technologies provided separate certificates to both the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), confirming compliance with the regulatory requirements.

Stock Exchange Notification

The certificates were addressed to both the National Stock Exchange of India Limited (company code: AUROPHARMA) and BSE Limited (company code: 524804). The filing ensures that all dematerialized securities continue to be listed on the same stock exchanges where the company's previously issued securities were traded.

This routine compliance filing demonstrates the company's adherence to SEBI regulations governing depositories and participants, maintaining transparency in securities handling and investor protection measures.

Aurobindo Pharma Limited has published a comprehensive public announcement detailing its ₹800.00 crore share buyback program, providing extensive regulatory disclosures and implementation procedures for shareholders. The pharmaceutical company's board approved this significant capital return initiative on April 6, 2026, with the public announcement published on April 8, 2026.

Buyback Structure and Implementation Details

The company will repurchase up to 54,23,728 equity shares at ₹1,475 per share through the tender offer route using BSE's stock exchange mechanism. The buyback represents 0.93% of total outstanding shares and will be implemented on a proportionate basis with special provisions for small shareholders.

Regulatory Compliance and Financial Framework

The buyback amount represents 3.93% and 2.62% of aggregate paid-up equity capital and free reserves based on standalone and consolidated financial statements as of March 31, 2025, respectively. This remains well within the statutory 10% limit under Companies Act and SEBI regulations.

Premium Structure and Market Positioning

The ₹1,475 buyback price offers attractive premiums across different timeframes:

Promoter Participation and Shareholder Benefits

Promoter and promoter group members, holding 51.82% of total shares, have confirmed their intention to participate in the buyback. The company will reserve 15% of buyback quantum for small shareholders as defined under SEBI regulations, ensuring broader participation benefits.

Implementation Process and Professional Services

The buyback will utilize BSE's acquisition window mechanism with comprehensive professional support:

Funding and Strategic Objectives

The company will fund the buyback through free reserves and permissible sources, excluding borrowed funds. Management outlined three primary strategic objectives: rewarding shareholders with enhanced returns, improving key financial ratios including earnings per share, and benefiting small shareholders through reserved allocation.

Regulatory Documentation and Compliance

The detailed public announcement includes comprehensive statutory auditor reports, permissible capital payment calculations, and extensive regulatory confirmations. The company has obtained necessary lender consents and confirmed compliance with all applicable regulations including Companies Act 2013 and SEBI Buyback Regulations 2018.